Healthcare of Disease Care?
We call it “healthcare.” But much of what we measure, incentivise, and deliver is not healthcare at all. It is disease care. And the distinction matters.
The Problem We Don’t Measure
Healthcare systems around the world are built on outcome measures. These measures define success, guide funding, and influence clinical decision-making. They shape policy, research, and industry priorities.
But what do these measures actually assess?
They predominantly track disease incidence, disease progression, hospitalisation rates, mortality, and surrogate biomarkers linked to pathology. In other words, they measure how well we respond after dysfunction has occurred.
What they do not measure is equally important. They do not assess whether people feel well, whether they function at a high physical or cognitive level, whether disease has been prevented, whether underlying causes have been addressed, or whether patients are living in a state of resilience and vitality.
We are not measuring health. We are measuring its absence—and, more specifically, how we manage that absence.
Disease Care vs Healthcare
Disease care and healthcare are not the same thing. Disease care is inherently reactive. It begins when pathology is present, and its goal is management, stabilisation, or delay of decline. It is also, undeniably, highly profitable.
Healthcare, by contrast, should be proactive, preventative, restorative, and individualised. It should aim to maintain or return the human organism to a state of optimal function.
Yet our current system largely rewards late-stage intervention rather than early optimisation. In many cases, it even penalises components of functional optimisation.
The Missing Variable: Patient Values
The outcomes we prioritise are not aligned with what patients actually value.
Patients consistently want to feel well, to have energy, to think clearly, to remain independent, to avoid disease where possible, and to recover fully if illness occurs. Very few aspire to long-term disease management, polypharmacy, or the stabilisation of decline.
Management of chronic illness is begrudgingly accepted, but it is rarely desired. And yet, a substantial proportion of our investment in research and therapeutics is directed toward this space. Again, it is highly profitable.
A Misnomer at the Core
“Healthcare” may be a misnomer.
What we have built is an extraordinarily sophisticated system for diagnosing disease, managing disease, and delaying the consequences of disease. But it is not a system designed to create health.
This is not a failure of clinicians. It is a structural issue—one driven by how success is defined and measured.
What Should We Be Measuring Instead?
If we are serious about healthcare, outcome measures must evolve.
We should be measuring functional capacity in terms of physical performance, cognitive function, and energy levels. We should be measuring healthspan—years lived in good health, not simply total lifespan. We should assess resilience, including the ability to withstand stress, illness, and injury, as well as the speed of recovery following physiological insult.
Preventative success should be a core metric, including reductions in disease incidence through early intervention and the maintenance of metabolic, hormonal, and mitochondrial function. Patient-reported outcomes must be central, capturing subjective wellbeing, mood, quality of life, and a sense of vitality.
Finally, we should measure causal resolution—whether interventions address underlying drivers of dysfunction rather than simply suppressing downstream symptoms.
A System-Level Consequence
This misalignment sits at the core of our failure to control the chronic disease epidemic, and the widespread suffering and loss of human potential we see across modern societies.
Access to disease care is essential—but it is not a substitute for healthcare.
A new cadre of professionals will be required. A new ethos. New institutions. The progressive differentiation between disease care and healthcare is not only likely—it may be inevitable.